Clinical Trials Logo

Clinical Trial Summary

Acute community-acquired pneumonia (CAP) refers to an acute infection of the lung parenchyma, occurring within the first 48 hours of hospitalization. It is a frequent, serious pathology with a strong economic impact. Viruses (rhinovirus, respiratory syncitial virus, influenza virus for the most common) and Streptococcus pneumoniae are the most frequently encountered pathogens. However, more than half of the PACs have no microbiological documentation. The management of CAPs is based on national and international recommendations. Several studies have shown imperfect compliance by clinicians with recommendations with a prognostic impact. The various published studies insist on the variability of the incidence, the type of pathogen, the severity and the economic impact, depending on the series. They also insist on the need to know the local epidemiology, in particular microbiological, in order to adapt the recommendations.


Clinical Trial Description

The objective of the study is to determine the epidemiological, clinical, biological and imaging characteristics of people admitted for acute community-acquired pneumonia. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05661513
Study type Observational
Source University Hospital, Strasbourg, France
Contact Loïc KASSEGNE, MD
Phone 33 3 69 55 01 88
Email loic.kassegne@chru-strasbourg.fr
Status Recruiting
Phase
Start date September 9, 2022
Completion date March 9, 2025